Amlodipine/valsartan/atorvastatin (CJ-30061) vs OLOMAX

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: Angiotensin II receptor / Calcium channel / HMG-CoA reductase · full Atherosclerotic Cardiovascular Disease pipeline

Amlodipine/valsartan/atorvastatin (CJ-30061)

Developed by HK inno.N Corporation

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule (combination)
Partial signal

NCT03639480 · Phase 3 · status unknown

The trial is randomized, blinded, and actively controlled, and measures blood pressure and LDL cholesterol, both accepted clinical endpoints for these conditions. However, results have not been posted yet, so whether the triple combination outperformed the two-drug regimens is unknown.

No aligned efficacy figure on record for this race.

OLOMAX

Marketed by Daewoong Pharmaceutical

small molecule (combination)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmlodipine/​valsartan/​atorvastatin (CJ-30061)OLOMAX
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

Amlodipine/​valsartan/​atorvastatin (CJ-30061)
—Not reported
OLOMAX
—Not reported

Non-HDL-C, % change

Amlodipine/​valsartan/​atorvastatin (CJ-30061)
—Not reported
OLOMAX
—Not reported

ApoB, % change

Amlodipine/​valsartan/​atorvastatin (CJ-30061)
—Not reported
OLOMAX
—Not reported

Lp(a), % change

Amlodipine/​valsartan/​atorvastatin (CJ-30061)
—Not reported
OLOMAX
—Not reported

3-point MACE (% with event)

Amlodipine/​valsartan/​atorvastatin (CJ-30061)
—Not reported
OLOMAX
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Amlodipine/valsartan/atorvastatin (CJ-30061): no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

OLOMAX: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amlodipine/valsartan/atorvastatin (CJ-30061)'s landscape · OLOMAX's landscape